The Pharmaceutical Needs Assessment (PNA) is a crucial part of the market entry system, and supports commissioning decisions based on patient needs, it is important that Health and Wellbeing Boards (HWBs) prepare PNAs to national comparable standards. The HWB has a duty to produce a Pharmaceutical Needs Assessment every three years. PNAs include:
- A statement of the pharmaceutical services provided that are necessary to meet needs in the area
- A statement of the pharmaceutical services that have been identified by the HWB that are needed in the area, and are not provided (gaps in provision)
- A statement of the other services which are provided, which are not needed, but which have secured improvements or better access to pharmaceutical services in the area
- A statement of the services that the HWB has identified as not being provided, but which would, if they were to be provided, secure improvements or better access to pharmaceutical services in the area
- A statement of other NHS services provided by a local authority, the NHS Commissioning Board (NHS England), an NHS Integrated Care Board (ICB) or an NHS Trust, which affect the needs for pharmaceutical services
- An explanation of how the assessment has been carried out (including how the consultation was carried out)
- A map of providers of pharmaceutical services
In March 2021, the Department of Health and Social Care (DHSC) announced that due to ongoing Covid-19 pressures across all sectors, the requirement to publish renewed PNAs would be suspended until October 2022 (see: Pharmaceutical Services Negotiating Committee - Latest news). DHSC's announcement means that renewed PNAs will not need to be published until April 2025 but Health and Wellbeing Boards will retain the ability to issue supplementary statements to respond to local changes and pharmaceutical needs during this time.
Appendix 13 - Analysis of PNA consultation [162kb] (This PDF is not fully accessible and may not be suitable for users of assistive technology. See: Accessible documents).